Compare Cytokinetics Inc (CYTK) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs iShares MSCI India ETF — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while iShares MSCI India ETF trades at $45.92 (market cap $5.73B). The key difference: Cytokinetics Inc is the larger of the two by market cap, and Cytokinetics Inc is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and iShares MSCI India ETF for 57 Days on average.
| CYTK | INDA | |
|---|---|---|
Market Cap | $8.62B | $5.73B |
Volume | 2,594,626 | 6,797,522 |
Sector | Health | Broad Market / Factor |
52-Week High | $87.26 | $55.29 |
52-Week Low | $54.76 | $45.42 |
Typical Hold Time | 19 Days | 57 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
INDA is trading at $46.12, down 1.31% with bearish technical signals dominating. The ETF faces headwinds from India's economic challenges including coal power shortages, monsoon concerns, and U.S. tariff tensions. Technical indicators show oversold conditions with RSI readings below 30, while moving averages signal strong bearish momentum. Recent news highlights structural issues in India's banking-heavy market composition despite overall economic growth.
The outlook remains cautious given India's energy security challenges and external trade pressures. Investment opportunity exists for long-term investors betting on India's growth story at current discounted levels, but risks include persistent power shortages, agricultural output concerns, and global trade tensions that could further pressure the ETF's performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
